• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.

作者信息

Allen Justin M, Schrock Alexa B, Erlich Rachel L, Miller Vincent A, Stephens Philip J, Ross Jeffrey S, Ou Sai-Hong Ignatius, Ali Siraj M, Vafai Davood

机构信息

Foundation Medicine, Inc, Cambridge, MA.

Foundation Medicine, Inc, Cambridge, MA.

出版信息

Clin Lung Cancer. 2017 May;18(3):e219-e222. doi: 10.1016/j.cllc.2016.12.006. Epub 2016 Dec 22.

DOI:10.1016/j.cllc.2016.12.006
PMID:28089157
Abstract
摘要

相似文献

1
Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 Fusion.复发的表皮生长因子受体（EGFR）突变型肺腺癌中循环肿瘤DNA的基因组分析揭示了一种获得性FGFR3-TACC3融合。
Clin Lung Cancer. 2017 May;18(3):e219-e222. doi: 10.1016/j.cllc.2016.12.006. Epub 2016 Dec 22.
2
Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.FGFR3-TACC3融合作为EGFR突变的非小细胞肺癌患者对EGFR酪氨酸激酶抑制剂潜在的旁路耐药机制的出现。
Lung Cancer. 2017 Sep;111:61-64. doi: 10.1016/j.lungcan.2017.07.006. Epub 2017 Jul 11.
3
Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.从肺腺癌中鉴定出复发性 FGFR3-TACC3 融合癌基因。
Clin Cancer Res. 2014 Dec 15;20(24):6551-8. doi: 10.1158/1078-0432.CCR-14-1337. Epub 2014 Oct 7.
4
Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.厄洛替尼治疗的 EGFR 外显子 19 突变型非小细胞肺癌患者的异质性耐药机制：持续存在的 FGFR3 突变、局部转化为 EGFR 突变型小细胞肺癌，以及获得性 T790M EGFR 突变。
Lung Cancer. 2017 Nov;113:14-17. doi: 10.1016/j.lungcan.2017.08.024. Epub 2017 Sep 1.
5
Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.厄洛替尼治疗同时存在KIF5B-RET融合基因和EGFR突变的肺腺癌的经验：1例罕见病例报告
J Thorac Oncol. 2014 May;9(5):e37-9. doi: 10.1097/JTO.0000000000000097.
6
FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.FGFR1/3 酪氨酸激酶融合定义了非小细胞肺癌的一个独特分子亚型。
Clin Cancer Res. 2014 Aug 1;20(15):4107-14. doi: 10.1158/1078-0432.CCR-14-0284. Epub 2014 May 21.
7
FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.FGFR3-TACC3融合蛋白通过在功能上替代EGFR/ERK信号传导，充当肿瘤耐药性的天然驱动因素。
Oncogene. 2017 Jan 26;36(4):471-481. doi: 10.1038/onc.2016.216. Epub 2016 Jun 27.
8
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.EML4-ALK 易位预示 EGFR 野生型肺腺癌患者的预后更好。
J Thorac Oncol. 2012 Jan;7(1):98-104. doi: 10.1097/JTO.0b013e3182370e30.
9
Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors.东亚非小细胞肺癌患者中表皮生长因子受体野生型或激活突变患者的化疗反应。
J Thorac Oncol. 2010 Sep;5(9):1424-9. doi: 10.1097/JTO.0b013e3181e9db73.
10
Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.在同时存在EML4-ALK融合基因和EGFR突变的肺腺癌中，吉非替尼有良好疗效。
J Thorac Oncol. 2010 Dec;5(12):2039-40. doi: 10.1097/JTO.0b013e3181f43274.

引用本文的文献

1
Conundrum of 3N: nasopharyngeal nonkeratinizing non-viral carcinoma-reappraisal of fusions and report of two consecutive cases with unusual molecular findings.3N难题：鼻咽非角化非病毒癌——融合基因的重新评估及两例具有异常分子发现的连续病例报告
Virchows Arch. 2025 May;486(5):1085-1090. doi: 10.1007/s00428-024-03877-7. Epub 2024 Jul 18.
2
Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC).融合作为表皮生长因子受体酪氨酸激酶抑制剂（EGFR TKIs）治疗后的一种获得性耐药机制以及晚期非小细胞肺癌（aNSCLC）中一个新的潜在靶点。
J Clin Med. 2022 Apr 28;11(9):2475. doi: 10.3390/jcm11092475.
3
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.第三代表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）抑制剂：耐药机制与处理
Nat Rev Clin Oncol. 2022 Aug;19(8):499-514. doi: 10.1038/s41571-022-00639-9. Epub 2022 May 9.
4
in Lung Cancers: Analysis of Patient Cases Reveals Recurrent Mutations, Fusions, Kinase Duplications, and Concurrent Alterations.在肺癌中：患者病例分析揭示复发性突变、融合、激酶重复和并发改变。
JCO Precis Oncol. 2018 Apr 19;2. doi: 10.1200/PO.17.00172. eCollection 2018.
5
A novel high-throughput molecular counting method with single base-pair resolution enables accurate single-gene NIPT.一种具有单碱基分辨率的新型高通量分子计数方法可实现精确的单基因 NIPT。
Sci Rep. 2019 Oct 7;9(1):14382. doi: 10.1038/s41598-019-50378-8.
6
Clinical Utility of Cell-Free DNA for the Detection of Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer.游离 DNA 在非小细胞肺癌中检测 ALK 抑制剂耐药的融合和基因组机制的临床效用。
Clin Cancer Res. 2018 Jun 15;24(12):2758-2770. doi: 10.1158/1078-0432.CCR-17-2588. Epub 2018 Mar 29.
7
Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.下一代测序液体活检分析验证用于高灵敏度广泛分子谱分析。
PLoS One. 2018 Mar 15;13(3):e0193802. doi: 10.1371/journal.pone.0193802. eCollection 2018.
8
Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.FGFR3-TACC3融合作为EGFR突变的非小细胞肺癌患者对EGFR酪氨酸激酶抑制剂潜在的旁路耐药机制的出现。
Lung Cancer. 2017 Sep;111:61-64. doi: 10.1016/j.lungcan.2017.07.006. Epub 2017 Jul 11.